What is Valted Seq?
Founded in 2019 and headquartered in Gaithersburg, Maryland, Valted Seq is a biotechnology firm dedicated to the genetic elucidation of neurodegenerative disease pathways. The company's core focus is on accelerating the development of novel therapeutics and diagnostics by leveraging advanced genetic insights. This strategic approach positions Valted Seq at the forefront of precision medicine for complex neurological conditions.
How much funding has Valted Seq raised?
Valted Seq has raised a total of $10M across 1 funding round:
Angel/Seed
$10M
Angel/Seed (2021): $10M with participation from DongKoo Bio&Pharma and OV Principal Investments
Key Investors in Valted Seq
DongKoo Bio&Pharma
DongKoo Bio & Pharma is a leading South Korean pharmaceutical company focused on innovative healthcare solutions, including prescription drugs and medical devices, with a strong emphasis on R&D to improve human health.
OV Principal Investments
OV Principal Investments is an investment entity that participates in strategic funding rounds, contributing capital to companies with high growth potential.
What's next for Valted Seq?
With this substantial backing, Valted Seq is poised for significant expansion and accelerated research and development. The enterprise-level financing will likely fuel further clinical trials, enhance its proprietary technology platforms, and potentially broaden its therapeutic pipeline. The company's strategic focus on neurodegenerative diseases, a critical area of unmet medical need, suggests a trajectory aimed at achieving significant milestones in drug discovery and diagnostic innovation.
See full Valted Seq company page
